Antibodies against a vaccine vector render T cells more susceptible to HIV-1 infection, say Perreau et al. on page 2717. Their results may help explain the failure of a recent HIV vaccine trial. The HIV-1 vaccine used in Merck's STEP trial relied on a weakened form of a common cold virus, Adenovirus 5 (Ad5), to carry bits of HIV into the body. One worry about the Ad5 vector was that widespread ...